Liu Jingzhen, Party Secretary and Chairman of China Pharmaceutical Group Co., Ltd. said that after the third phase of international clinical trials, inactivated vaccines can enter the approval process. It is expected that the vaccine will be available at the end of February this year, and the output of this batch of vaccines in Beijing can reach10.20 billion. Even the annual output of Wuhan can reach 654.38+0 billion doses.
According to the safety of the vaccine, the immunization, epidemic prevention and safety of the vaccine have been achieved in the evaluation of many clinical trials. The safety and immunogenicity of the vaccine were verified by the standard. Compared with the first-phase clinical trial, the safety and immunogenicity of the vaccine in a wider range of people have been further demonstrated, and the information available all over the world is completely open. This means that China's medical level and intellectual property system are confident enough.
Regarding the protection rate of vaccine, Liu Jingzhen, Party Secretary and Chairman of China Pharmaceutical Group Co., Ltd. said that the protection rate of vaccine after one injection is about 97%, because antibody production is slow and grows slowly like a curve. So it usually takes about half a month to reach the level of resistance to starlight virus. If two shots of vaccine are given, the protection rate can even reach 100%.
Moreover, at present, this vaccine has been patented by the state and proved to be safe and effective, and will be mass-produced soon. It can be said that this vaccine has no side effects and is safe. We should keep hope for the development of key technologies and future technologies in our country. Our country's scientific research technology and level are gradually improving, so we should continue to be optimistic!